Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
NexImmune had reported a significant reduction in its cash reserves in the last six months. Image Credit: DesignPrax / Shutterstock.
Source: Pharmaceutical Technology
NexImmune became the latest in a row of companies to announce layoffs as a cash-reduction measure this year, as it is reducing its workforce by 53% as of 5 September 2023. The US-based company will lay off 25 of its full-time employees along with its CFO, John Trainer, but Trainer will stay as a consultant. NexImmune had reported a significant reduction in its cash reserves in the last six months. As per the company’s Q2 financials, it only had $16.3m remaining as of 30 June, compared to $34.6m on 31 December 2022.
The company also has paused the development of its three adoptive T cell therapies that use T cells harvested from tumours, which are then activated and expanded before reinfusion to target and destroy cancer cells. NexImmune CEO Kristi Jones stated: “The workforce reduction protects our core capabilities to advance novel therapeutic candidates and our multiplex validation of functional antigen-specific T cell responses while giving us additional flexibility to manage our business.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic Source: Pharmaceutical Technology
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy